In agreement with these findings, researchers showed that blocking IL‐18 bioactivity using rhIL‐18BPa or anti‐IL‐18 reduced the severity of both TNBS colitis111 and DSS colitis,36 respectively. This evidence concerns the gene IL18 and colitis.